Evidence map›Paper›PMID 27758873›Full record

ArticleBlood2016

Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and human T cells.

Scott N Furlan, Benjamin Watkins, Victor Tkachev, Sarah Cooley, Angela Panoskaltsis-Mortari, Kayla Betz, Melanie Brown, Daniel J Hunt, John B Schell, Katie Zeleski and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Milestones in acute GVHD pathophysiology.Frontiers in immunology · 2022
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Biomarkers for Allogeneic HCT Outcomes.Frontiers in immunology · 2020
    Review
  17. Article
  18. Article
  19. Expansion of IL-17A-secreting CD8Blood advances · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Scott N FurlanBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA.ORCID 0000-0003-3007-9840
Benjamin WatkinsBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA.
Victor TkachevBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA.
Sarah CooleyDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN; and.ORCID 0000-0001-8953-6730
Angela Panoskaltsis-MortariDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN; and.
Kayla BetzBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA.
Melanie BrownBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA.
Daniel J HuntBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA.
John B SchellBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA.
Katie ZeleskiBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA.
Alison YuBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA.
Cynthia R GiverDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA.
Edmund K WallerDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA.
Jeffrey S MillerDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN; and.
Bruce R BlazarDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN; and.
Leslie S KeanBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA.
Seattle Children's Hospital · USUniversity of Minnesota · USEmory University · US

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
YNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI ALTMAN, JOHN DAVID · 1985 to 2011
$114.0M
Transplant Tolerance in Non-Human PrimatesU19AI051731 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI LARSEN, CHRISTIAN P. · 2002 to 2022
$54.1M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHARPE, ARLENE H. · 2003 to 2023
$42.5M
Novel Biologic Therapies for GVHDR01HL095791 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI KEAN, LESLIE S · 2010 to 2025
$13.3M
IN VIVO PREVENTION OF MURINE GVHDR01AI034495 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1993 to 2016
$6.2M
T-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4M
NCI NIH HHS P01 CA065493NCRR NIH HHS P51 RR000165NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL095791NIAID NIH HHS P01 AI056299NIAID NIH HHS R01 AI034495NIAID NIH HHS U19 AI051731NIH HHS P51 OD010425
6 · The paper itself

Abstract

One of the central challenges of transplantation is the development of alloreactivity despite the use of multiagent immunoprophylaxis. Effective control of this immune suppression-resistant T-cell activation represents one of the key unmet needs in the fields of both solid-organ and hematopoietic stem cell transplant (HCT). To address this unmet need, we have used a highly translational nonhuman primate (NHP) model to interrogate the transcriptional signature of T cells during breakthrough acute graft-versus-host disease (GVHD) that occurs in the setting of clinically relevant immune suppression and compared this to the hyperacute GVHD, which develops in unprophylaxed or suboptimally prophylaxed transplant recipients. Our results demonstrate the complex character of the alloreactivity that develops during ongoing immunoprophylaxis and identify 3 key transcriptional hallmarks of breakthrough acute GVHD that are not observed in hyperacute GVHD: (1) T-cell persistence rather than proliferation, (2) evidence for highly inflammatory transcriptional programming, and (3) skewing toward a T helper (Th)/T cytotoxic (Tc)17 transcriptional program. Importantly, the gene coexpression profiles from human HCT recipients who developed GVHD while on immunosuppressive prophylactic agents recapitulated the patterns observed in NHP, and demonstrated an evolution toward a more inflammatory signature as time posttransplant progressed. These results strongly implicate the evolution of both inflammatory and interleukin 17-based immune pathogenesis in GVHD, and provide the first map of this evolving process in primates in the setting of clinically relevant immunomodulation. This map represents a novel transcriptomic resource for further systems-based efforts to study the breakthrough alloresponse that occurs posttransplant despite immunoprophylaxis and to develop evidence-based strategies for effective treatment of this disease.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationT-Lymphocytes, CytotoxicT-Lymphocytes, Helper-InducerAcute DiseaseAllograftsAnimalsDisease Models, AnimalFemaleHaplorhiniHumansInflammationInterleukin-17MaleInterleukin-17

Identifiers

PMID27758873
PMCPMC5123196
OpenAlexW2528243887

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.